Category PRECISION MEDICINE

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Immunotherapy has unleashed a revolution in care for some cancer patients. But most immunotherapies help only a small subset of patients, meaning doctors often have to resort to a trial-and-error process to determine who might actually benefit from the novel treatments. Now, scientists have developed a new metric they believe can help predict whether patients will respond

Read More


Nivolumab Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show

The immune checkpoint inhibitor nivolumab may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 clinical trial suggest. A three-year survival analysis of the trial, called ATTRACTION-2 (NCT02267343), showed that the treatment significantly extended patients’ lives and the time they

Read More


Study identifies interaction that promotes cancerous state in cells

When the machinery that guides the transition of stem cells to somatic cells doesn’t shut down properly, cells can become cancerous. Identifying the mechanisms that impede those processes would offer scientists a target for cancer research. Purdue University scientists, led by Humaira Gowher, an associate professor in the Department of Biochemistry, have discovered the epigenetic process that

Read More


Blocking pro-fibrosis signaling pathway may improve immunotherapy of metastatic breast cancer

A Massachusetts General Hospital (MGH) research team has found that the overgrowth of connective called fibrosis may block the effectiveness of immunotherapies against metastatic breast cancer. Their report published in PNAS also finds that plerixafor, a drug approved to mobilize blood system stem cells in the treatment of lymphoma and multiple myeloma patients, can reduce fibrosis in

Read More


Mesoblast submits Ryoncil’s completed biologics license application to US FDA for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).

Mesoblast Limited today announced that it has submitted its completed Biologics License Application (BLA) to the United States Food and Drug Administration (US FDA) for Ryoncil™ (remestemcel-L), its lead allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease (SRaGVHD). Mesoblast filed the final module of the rolling BLA submission,

Read More


Stem Cells, CRISPR and Gene Sequencing Technology are Basis of New Brain Cancer Model

Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type of cancer model to study in vivo how glioblastoma, the most common and aggressive form of brain cancer, develops and changes over time. “We have developed stem cell models that are CRISPR-engineered to have tumor-associated driver mutations

Read More